SHPH
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) 10Y Growth Potential Analysis (2026)
No material changes this month.
Revenue Growth Drivers
No disclosed 5-year revenue CAGR limits evidence of durable top-line compounding, leaving SHPH behind peers with measurable multi-year growth trajectories.
Negative TTM ROIC suggests current capital deployment is not yet generating scalable returns, reducing reinvestment capacity versus stronger-growth peers.
Zero reported capex-to-revenue implies limited visible investment intensity, which can constrain expansion if the business lacks funded growth projects.
Negative interest coverage indicates earnings are insufficient to comfortably service financing costs, weakening the ability to fund revenue expansion relative to peers.
Market Tailwinds
No segment concentration or market-share data is provided, so there is no evidence of a differentiated demand engine versus peers.
Absent revenue CAGR disclosure, the company lacks verified proof that external demand is translating into sustained multi-year growth.
Negative profitability metrics imply any market opportunity is not yet converting into durable commercial scale, unlike better-executing peers.
The available metrics show financial strain rather than expanding end-market capture, which weakens long-term growth visibility versus peers.
Scalability Expansion
Negative ROIC and negative interest coverage indicate the current model is not scaling efficiently enough to support compounding revenue.
The extremely negative cash conversion cycle suggests working-capital dynamics are distorted, which can hinder repeatable expansion versus peers.
No evidence of positive FCF, R&D intensity, or capex deployment is provided, limiting proof of reinvestment-led scaling capacity.
Compared with scalable peers, SHPH shows weaker signs of operating leverage and funding flexibility needed for multi-year expansion.
Constraints Limitations
Negative TTM ROIC is a structural constraint because it implies incremental capital is not currently compounding value or revenue efficiently.
Negative interest coverage creates financing fragility, which can cap growth investment and reduce flexibility versus less levered peers.
The lack of disclosed growth history prevents confirmation of durable expansion, increasing uncertainty around long-term scalability.
Working-capital intensity appears extreme, which can absorb cash and limit the company’s ability to fund sustained growth.
Overall Score
SHPH appears structurally constrained for long-term compounding because current capital efficiency, coverage, and working-capital dynamics are weaker than peers, and verified growth evidence is limited.
Score Driver: Negative Capital Efficiency
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Shuttle Pharmaceuticals Holdings, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
